运用Cox模型和Sokal,Hasford积分系统对慢性髓细胞白血病患者的预后分析

本研究分析影响慢性髓细胞白血病（CML）患者预后的危险因素。采用回顾性研究分析204例CML患者的临床及实验室检查资料，用Kaplan—Meier法绘制生存曲线，用Logrank检验比较生存率，运用Cox回归模型进行单因素及多因素分析，并分别计算Sokal，Hasford积分。结果表明：204例患者中位生存时间为50（32—65）月，5年生存率32．3％（95％CI，23．7％-42．6％）。干扰素组与羟基脲组的中位生存时间分别为56（41—67）月和41（19—56）月，5年生存率分别为45．4％（95％CI，37．5％-54．2％）和26．8％（95％CI，21．6％-33．3％）（P〈0．001）。经Cox回归分析，Ph染色体阴性、乳酸脱氢酶含量增高、外周血嗜碱性粒细胞≥10％、出现有核红细胞、骨髓原粒细胞≥4％、骨髓原始＋早幼粒细胞≥10％和红细胞压积降低是CML预后不良的危险因素，而治疗方法也是影响CML预后的重要因素。羟基脲组经Sokal积分检验，高危组占72．9％，中危组占21．5％，而低危组占5．6％，中位生存时间分别为34（23—49）月、43（32—58）月、50（38—62）月；干扰素组经Hasford积分检验，高危组占17．6％，中危组占25．1％，低危组占57．3％，中位生存时间分别为44（33—57）月、56（45—70）月和66（52—76）月。结论：Ph染色体、乳酸脱氢酶含量、红细胞压积、外周血嗜碱性粒细胞、出现有核红细胞、骨髓原始和早幼粒细胞以及治疗方法是影响CML预后的重要因素。以Sokal积分系统评价羟基脲组患者不能很好区分危险组，而Hasford积分系统评价干扰素组患者，能够区分危险组。     

Routinely collected general practice data aids identification of people with hyperglycaemia and metabolic syndrome.

AIMS: To assess the performance of a risk score comprising data routinely available in general practice records (age, gender, body mass index, family history of diabetes, smoking habits and prescribed anti-hypertensive drugs or steroids) in detecting diabetes, impaired glucose tolerance and metabolic syndrome. METHODS: In a population-based, cross-sectional study in a semi-rural general practice in Jutland, Denmark, Cambridge Risk Scores were calculated for 1355 patients without known diabetes (69% response rate) who completed questionnaires and underwent anthropometric measurement and an oral glucose tolerance test. RESULTS: Prevalences of diabetes, impaired glucose tolerance and metabolic syndrome were 2.29% (95% CI: 1.56-3.23), 6.64% (95% CI: 5.38-8.10) and 13.4% (95% CI: 11.5-15.2), respectively. Area under the ROC curve for the risk score and diabetes was 83.8% (75.9-91.7) and for metabolic syndrome [European Group for the Study of Insulin Resistance (EGIR)] was 78.1% (74.6-81.6). Twenty per cent of the population had a risk score above 0.246; at this threshold the sensitivity to detect diabetes was 71.0% (53.4-83.9), the specificity 81.2% (79.0-83.2), positive predictive value 8.1% (6.6-10.0) and likelihood ratio 3.77 (2.94-4.85). For metabolic syndrome (EGIR) corresponding values for sensitivity were 50.3% (43.1-57.5), specificity 84.7% (82.5-85.6), positive predictive value 33.6% (28.2-39.4), and likelihood ratio 3.28 (2.69-4.00). CONCLUSIONS: Undiagnosed hyperglycaemia and metabolic syndrome are common. The Cambridge Risk Score is a practical first step in a screening procedure to identify individuals with these disorders who might benefit from diagnostic testing or to direct preventive interventions.     

不同剂量普伐他汀治疗急性脑梗死的疗效和安全性研究

目的：探讨不同剂量普伐他汀在脑梗死急性期治疗的可行性、降脂疗效及安全性。方法：脑梗死急性期病人146例，随机分为3组，A组（50例）为对照组，B组（49例）每晚服普伐他汀10mg，C组（47例）每晚服普伐他汀20mg，观察30d。比较治疗前后血脂、神经功能缺损评分、生化指标等变化，并记录服药后不良反应。结果：各组总胆固醇（TC）、低密度脂蛋白（LDL-C）、超敏C-反应蛋白（hs-CRP）在治疗后都有所下降，C组下降最显著，B组次之，A组下降程度较小。A组TG治疗前后无明显变化，B组和C组TG治疗后有所下降，两组间无明显差别。脂蛋白（Lpa）在A组治疗后有下降，B组无明显变化，C组较前轻度升高。各组治疗前后神经功能缺损评分均有降低，但各组之间比较无明显差异（P〉0.05）。观察期间所有病人均能耐受普伐他汀，治疗前后肝、肾功能、肌酸激酶（CK）等无明显变化。结论：在脑梗死急性期应用普伐他汀（每日10～20mg）是安全可行的，且每日20mgTC、TG降低更显著，脑梗死急性期的病人应用普伐他汀后取得较好的降脂疗效，神经功能缺损评分的改善有待较长期观察。     

Regional Variation and Use of Exception Letters for Cadaveric Liver Allocation in Children with Chronic Liver Disease

The Pediatric End-Stage Liver Disease (PELD) score was designed to reduce subjectivity in liver allocation and to advantage patients with a higher probability of waiting list mortality. The aims of this study were to determine the impact of PELD implementation for children with chronic liver disease and to assess whether PELD met its goal of standardization of liver allocation for children. This study used data reported to the United Network for Organ Sharing (UNOS) registry for children with chronic liver disease receiving primary cadaveric liver transplant between January 2000 and December 2001 (pre-PELD) and March 2002 and July 2003 (PELD). PELD reduced the percentage of children transplanted while in an intensive care unit and as status 1. A calculated PELD score was used for allocation in only 52% of recipients. Thirty percent were status 1 at transplant and PELD scores granted by exception were used for allocation in 18% of patients. There was regional variation in PELD score at allocation and use of exception scores with a significant relationship between PELD score and percentage of exception cases. Regional variation suggests that PELD has not resulted in standardization of listing practices in pediatric liver transplantation.     

Autologous implantation of chondrocytes on a solid collagen scaffold: clinical and histological outcomes after two years of follow-up

Abstract From our overall experience in 56 patients, we here report the treatment with matrix-induced autologous chondrocyte implantation (MACI) of 35 patients suffering from knee cartilage defects measuring about 4 cm², and followed for a minimum of 6 months. A total of 36 knees were treated (1 patient on both knees) and clinically observed for 22 months (in some cases for over 39 months), in accordance with a standardised protocol. Subjective parameters (pain, well-being, functional state, symptoms during specific activity) and objective outcomes (IKDC score and Lysholm and Tegner scores) were recorded. One or 2 years after implantation, some biopsies of the regenerated cartilage were histologically evaluated. The subjective parameters (VAS pain score, 2.80±1.49, p<0.0001; change vs. basal score, 2.72) promptly normalized after 1 month, as did the objective ones (IKDC score after 6 months, 1.53±0.59, p<0.0001; change vs. basal score, 1.78). Similar results were observed after the treatment of a femoropatellar kissing lesion. The three cartilage biopsies that were analysed from different patients showed a tissue positivity to immunohistochemical markers of hyaline cartilage. The conclusions of this preliminary analysis are that the clinical outcome and histological evaluation suggest that MACI is able to relieve pain and restore the functionality of the knee, and that the treatment appears capable of regenerating hyaline cartilage.     

Flow cytometric analysis of localized adenocarcinoma of the prostate: the use of archival DNA analysis in conjunction with pathological grading to predict clinical outcome following radical retropubic prostatectomy

Fifty-four specimens from patients undergoing radical prostatectomy for clinically confined prostate cancer between 1983 and 1987 were reviewed to determine the potential for flow cytometric (FCM) analysis of DNA ploidy and replication rate to predict disease recurrence. Each specimen was deparaffinized for FCM analysis and the pathology slides were reviewed by a single pathologist. FCM characteristics were correlated with pathological grade and stage, and both were correlated with disease status. In this series of patients, routine FCM analysis of DNA ploidy and replication rate failed to significantly enhance the ability of standard histopathological grading to predict disease recurrence in patients having clinically localized prostate cancer. Aneuploid tumors pathologically confined to the prostate did not appear to negatively affect prognosis.     

时滞系统鲁棒稳定性的新判据

基于Ｌｙａｐｎｕｏｖ泛函方法，研究了满足匹配条件的不确定性时滞系统的鲁棒稳定性及具有稳定度β〉０鲁棒稳定性，给出了已有结果不能推出的新判据。这些新判据对已有结果难以使用的情况下也可有是有效的，或有时减少了已有结果的保守性。     

Rockall危险性积分在急性上消化道出血中的应用

目的：探讨Rockall危险性积分在急性上消化道出血中的应用。方法：262例按Rockall危险性积分进行评分，并分为低危组（0～3）、中危组（4～7）、高危组（≥8）。结果：高危组与中危组相比再出血率差异无统计学意义（P〉0．05）。高危组与中危组相比死亡率明显升高（P〈0．05）。结论：Rockall危险性积分对急性上消化道出血患者的病情评估具有重要的意义。     

基于术前脾脏CT影像组学列线图预测胃癌的浆膜浸润

目的：联合临床检验指标及影像学特征构建一种能够术前识别胃癌浆膜浸润的模型。方法：选取2015年1月至2019年12月温州医科大学附属第一医院经病理证实的656例胃癌患者,采用随机数字表法分为建模组（394例）和验证组（262例）。收集建模组患者的脾脏影像学资料,对收集的数据进行套索回归并选取差异有统计学意义的特征来构建浆膜浸润预测模型。在最大约登指数下取肿瘤浸润风险评分截断值将患者分为高危组（238例）和低危组（418例）,然后与其他浸润相关因素如BMI、年龄、性别、高血压、糖尿病等进行单变量和多变量Logistic回归分析,结合显著的独立影响因素共同建立可视化的浆膜浸润预测列线图。结果：将患者以肿瘤浸润评分≤-0.335分为低危组,＞-0.335为高危组,经验证组验证,建模组和验证组的诊断准确性较为一致（P＜0.001）。经浸润影响因素的单变量和多变量Logistic回归分析发现,影像组学肿瘤浸润评分（OR=2.9,95%CI=2.1～4.2,P＜0.001）、术前低白蛋白（OR=1.3,95%CI=1.2～3.1,P=0.003）、血小板与淋巴细胞比值（OR=1.8,95%CI=1.2～2.7,P=0.004）、肿瘤分化程度（OR=2.6,95%CI= 1.8～3.7,P＜0.001）是浆膜浸润的独立影响因素。基于这4个指标建立的预测模型能够较为准确地预测浆膜浸润风险,其AUC值为0.733。结论：基于脾脏影像的肿瘤浸润评分联合其他临床因素可准确预测胃癌浆膜浸润与否,提高诊断精度。